ÉR

Érika Ruiz-García

Instituto Nacional de Cancerología

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Horacio Astudillo‐de la Vega

Instituto Nacional de Cancerología

César López‐Camarillo

Universidad Autónoma de la Ciudad de México

Laurence A. Marchat

Instituto Politécnico Nacional

G. Calderillo-Ruiz

Instituto Nacional de Cancerología

C. Díaz

Instituto Nacional de Cancerología

Abelardo Meneses-García

Instituto Nacional de Cancerología

Marytere Herrera

Instituto Nacional de Cancerología

Leonardo S. Lino‐Silva

Instituto Nacional de Cancerología

ÁH

Ángel Herrera‐Gómez

Instituto Nacional de Cancerología

Jorge Alberto Guadarrama-Orozco

Universidad de Tijuana

Cooperative Institutions

Instituto Nacional de Cancerología

290

Universidad Nacional Autónoma de México

108

Mexican Social Security Institute

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

The University of Texas MD Anderson Cancer Center

Dana-Farber Cancer Institute

Harvard University

Vanderbilt University Medical Center

Centro Medico Nacional Siglo XXI

Instituto Nacional de Cancerología

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Association of Prognostic Nutritional Index as a predictive factor of survival in patients with colorectal cancer in a Mexican population

Annals of Oncology (2019)

C. Díaz G. Calderillo-Ruiz Maritza Ramos-Ramírez Marytere Herrera Felipe A. Calvo

10.1093/annonc/mdz155.342

Cite

Citations (6)

Neoadjuvant chemoradiotherapy or chemotherapy preoperative on outcomes of patients with locally advanced or irresecable gastric cancer(LAGC)

Annals of Oncology (2017)

C. Díaz Germán Calderillo Erika Ruiz‐García Marytere Herrera López Horacio

Epirubicin

Chemoradiotherapy

10.1093/annonc/mdx261.093

Cite

Citations (1)

Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe: A Strategy Proposed by the LEGACy Consortium

Journal of Cancer Education (2025)

Juan Antonio Carbonell-Asíns Elena Jiménez-Martí Sergio Romero Eduardo García Ana Miralles-Marco

Abstract Gastric cancer (GC) has a poor prognosis. The LEGACy consortium has been established to enhance GC outcomes though improved primary and secondary prevention strategies. We performed an educational intervention study using an online module to disseminate knowledge about GC risk factors and symptoms to the general population. Participants were recruited through various media channels and were exposed to an online questionnaire to assess their knowledge, before and after the educational intervention. The educational intervention included an informative brochure and a short video providing essential information about GC. Primary outcome was to evaluate the overall knowledge (global score) before and after the intervention. A total of 1034 participants were evaluated before the intervention. Of those, 866 also completed the short-term and 362 the long-term questionnaire after the intervention, respectively. On a scale of 0 to 17, the baseline global score mean was 9.4 (3.2). Results showed an increase in the average global knowledge score by 1.80 (95% CI: 1.63–1.96, p < 0.001) and 1.81 (95% CI: 1.65–1.96, p < 0.001) points after completing the short and long-term questionnaires compared to the baseline respectively for all individual questions ( p < 0.05). This interventional study showed significantly improved knowledge in most domains on GC risk factors, signs, and symptoms which could be a useful strategy for promoting cancer prevention. ClinicalTrials.gov Identifier: NCT04019808.

Baseline (sea)

10.1007/s13187-025-02578-2

Cite

Citations (0)

1101 POSTER Identification of KRas Mutational Polymorphism by Molecular Analysis Using High-resolution Melting System in a Large MCRC Mexican Sample

European Journal of Cancer (2011)

Horacio Astudillo‐de la Vega P. Romero-Garcia J.A. Silva R. Villalobos-Valencia Viviana Vázquez‐Rivera

High Resolution Melt

Identification

10.1016/s0959-8049(11)70744-4

Cite

Citations (0)

Outcome of young patients with rectal adenocarcinoma

Journal of Gastrointestinal Oncology (2017)

Leonardo S. Lino‐Silva Rosa A. Salcedo‐Hernández Erika Ruiz‐García Alberto M. Leon‐Takahashi Leticia García-Pérez

There is an increase in the incidence of rectal carcinoma (RC) in young patients.We analyzed 175 patients with sporadic RC which were divided in two groups according their age: 24 patients ≤40 years and 151 patients >40 years and the two groups were compared in order to determine if the outcomes (especially overall 5-year survival) were different.Overall 5-year survival was similar between groups (67.1% for patients over 40 years and 70.4% for those under 40 years, P=0.803). The only differences found were in some clinicopathologic features: patients <40 years showed more dissected lymph nodes (LNs) (21 vs. 15, P=0.035) and more LN metastasis (54.2% vs. 39.1%, P=0.048). In multivariate analysis factors associated with worse survival were incomplete resection and no use of neoadjuvant therapy. Age did not demonstrate prognostic value (P=0.077).RC in people ≤40 years demonstrated greater number of LN harvested and LN metastases but oncologic outcomes, especially 5-year overall survival, were similar between groups.

10.21037/jgo.2016.09.04

Cite

Citations (5)

1969. SARS-CoV-2 seroprevalence among patients with cancer and healthcare workers from an oncology referral center during the first year of COVID-19 vaccination in Mexico

Open Forum Infectious Diseases (2022)

Rodrigo Villaseñor-Echavarri Daniel De‐la‐Rosa‐Martinez Emmanuel Frías-Jiménez Alexandra Martin‐Onraët Érika Ruiz-García

Abstract Background Cancer patients (CPs) with COVID-19 have an increased risk of adverse outcomes. In addition, CPs seem to have a lower immune response to SARS-CoV-2 vaccination. This study aimed to evaluate SARS-CoV-2 spike antibodies (anti-S Abs) following COVID-19 vaccination in CPs and healthcare workers (HCWs). Methods We conducted a point-seroprevalence study in CPs and HCWs who received a two-dose scheme with either BNT162b2, AZD1222, or Sputnik-V vaccine. We measured anti-S Abs by quantitative immunoassay to assess humoral immune response. Besides, we quantified anti-nucleocapsid antibodies in a subgroup of individuals to determine prior infection. We compared anti-S Abs titers in both groups and stratified by vaccine type, prior infection, and clinical characteristics. We conducted a multivariate logistic regression to determine variables associated with a poor humoral response. Results Six hundred forty-one individuals were included: 174 (27%) CPs and 467 (73%) HCWs. The median anti-S Abs titter was higher among HCWs compared to CPs (2568 U/mL vs. 1807 U/mL, p=0.002). Both CPs and HCWs with prior infection had higher anti-S Abs titter (p< 0.001). Regardless of the time since vaccination, a higher proportion of subjects with titers < 250 U/mL was observed in CPs (p< 0.001) (Fig 2). In the multivariate analysis, older age (p=0.036), AZD1222 (p=0.003), and Sputnik-V (p=0.020) were associated with lower humoral response among the entire cohort. SARS-CoV-2 spike antibody titers among cancer patients and healthcare workers. Global differences in anti-S Abs titers between CPs and HCWs groups (a) and antibody titers in CPs and HCWs groups stratified by type of received vaccine (b). Abbreviations: CP: Cancer patients, HCW: Healthcare workers. SARS-CoV-2 spike antibody titers according to time since vaccination among cancer patients and healthcare workers. Abbreviations: CP: Cancer patients, HCW: Healthcare workers. Conclusion In this study, both CPs and HCWs showed an adequate response to vaccination; however, CPs had lower anti-S Abs titers and a faster decline over time. Based on our results, new strategies should be assessed to sustain the humoral response to vaccination and thus decrease the COVID-19 burden among the oncologic population. Disclosures All Authors: No reported disclosures.

Seroprevalence

Antibody titer

10.1093/ofid/ofac492.1594

Cite

Citations (0)

Characteristics of Hepatocellular Carcinoma by Sex in Mexico: A Multi-institutional Collaboration

Javier Melchor-Ruan Luis Santiago-Ruiz Blanca Murillo-Ortíz Samuel Rivera Yelda A. Leal

Liver cancer is the fourth leading cause of cancer-related death worldwide. In Mexico, there is a high burden of liver cancer mortality in rural states, which affects both women and men equally. Thus, we aimed to describe the demographic and clinical characteristics of hepatocellular cancer (HCC) by sex in Mexico. Demographic and clinical information were extracted retrospectively from the medical records of patients with HCC initially treated (2015-2022) at participating institutions of a national survey across the country. The male-to-female ratio was calculated at the national and regional levels and the results were stratified by sex. Among 697 HCC patients, the age at diagnosis was 65.4±11.9y and 20% were diagnosed at ≥75y. The male-to-female ratio was 1.4:1, ranging from 1:1 in the northwestern and southwestern regions to 2.1:1 in the western region. The proportion of cirrhosis was similar between sexes; however, the etiologies for cirrhosis differed: cryptogenic cirrhosis was higher in women and alcohol consumption was higher in men. Men had a higher proportion of advanced HCC, poor/undifferentiated tumors, and ≥4 nodules than women. HCC in the Mexican population affects men and women at a 1.4:1 male-to-female ratio. This unique proportion by sex could be explained by the differences in the prevalence of risk factors across our heterogeneous country.

10.20944/preprints202405.1998.v1

Cite

Citations (1)

Epidemiological Data of Patients with Gastric Cancer in Mexico

Annals of Oncology (2012)

G. Ruiz N Reynoso C. Díaz Erika Ruiz‐García E. Trejo

10.1016/s0923-7534(20)33345-7

Cite

Citations (0)

Un adecuado número de ganglios linfáticos puede ser obtenido en la mayoría de los especímenes quirúrgicos de resección radical de recto después de tratamiento neoadyuvante

Revista Española de Patología (2015)

Leonardo S. Lino‐Silva Rosa A. Salcedo‐Hernández Kuauhyama Luna‐Ortiz Alejandro Padilla-Rosciano Abelardo Meneses-García

10.1016/j.patol.2015.04.001

Cite

Citations (1)

Molecular analysis of KRAS polymorphism mutation using a high-resolution melting system in a large mCRC patients sample in Mexico.

Journal of Clinical Oncology (2011)

Horacio Astudillo Érika Ruiz-García V. M. Vazquez J. Bastarrachea P. Romero-Garcia

e14132 Background: The KRAS-MAPK, PI(3)K signaling pathways form a network that play a central role in tumorigenesis. Mutations in codons 12, 13 and also 61 cause an activation of the KRAS protein. These mutations are frequently found in human tumors. The presence of KRAS mutation is predictive of nonresponse and shorter survival in patients treated by anti-epidermal growth factor receptor (anti-EGFR) antibody for metastatic colorectal cancer (mCRC). Methods: We retrospectively collected paraffin embedded tumors from 807 patients with mCRC diagnosis from different Hospitals in Mexico. Mutation detection in KRAS codons 12 and 13 were determined. The tests were performed in a LightCycler 2.0 system using the LightMix Kit KRAS mutation (TIB-Molbiol). Results: Patients with KRAS wild-type tumors (n = 495; 61%) and patients with KRAS mutated (n=312; 39%) shown the following polymorphism: Gly12Ser (GGT>AGT) (148/312, 47%); Gly12Asp (GGT>GAT) (50/312, 16%); Gly12Val (GGT>GTT) (22/312, 7%); Gly13Asp (GGT>GAC) (20/312, 6%); Gly13Cys (GGT>TGT) (16/312, 5%); Gly12Arg (GGT>CGT) (13/312, 4%); Gly12Cys (GGT>TGT) (12/312, 4%); Gly12Ala (GGT>GCT) (11/312, 4%). Conclusions: KRAS mutation status was according with international previous reports (n=312; 39%), and it was more associated with the mutation polymorphism Gly12Ser (GGT>AGT; 148/312; 47%). Outcome measures in KRAS wild-type patients treated with a cetuximab-based regimen was not evaluated because of the early treatment stage.

10.1200/jco.2011.29.15_suppl.e14132

Cite

Citations (0)